<DOC>
	<DOCNO>NCT02127463</DOCNO>
	<brief_summary>This Phase II/III , vehicle control , double mask , single center study . A single eye 60 individual mild moderate non-exudative Age-Related Macular Degeneration ( AMD ) randomly assign receive either topical 1 % MC-1101 vehicle control 2 year . The study design ass efficacy , safety , tolerability MC-1101 patient . An analysis primary secondary endpoint conduct subject complete Baseline , 1 , 3 , 6 , 12,18 24 month .</brief_summary>
	<brief_title>Phase II/III Study Efficacy Safety MacuCLEAR MC-1101 Treating DryAge-Related Macular Degeneration</brief_title>
	<detailed_description>MC-1101is topically administer drug previous clinical study prove get back eye . MC-1101is 505 ( b ) 2 compound FDA Fast Track Status . It strong , vasoactive drug intend increase choroidal blood flow .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Males female age ≥ 50 year ≤ 85 year Females : At least 1year since last menstrual period surgically sterilize 20/80 good ETDRS best correct visual acuity Early intermediate nonexudative AMD ( AMD category 3 3b AgeRelated Eye Disease Study ( AREDS ) Report No . 8 AMD Categories Willing able sign inform consent , comply study protocol requirement , undergo least 2.5 hour test visit Able reliably complete biophysical test Willing take AREDS2 base formula vitamin indicate Past current exudative AMD central geographic atrophy study eye ; ( AMD Category 4 AgeRelated Eye Disease Study ( AREDS ) Report No . 8 AMD Categories ) Past current retinal choroidal vasculopathy study eye ( e.g . serous hemorrhagic pigment epithelial detachment , polypoidal choroidal vasculopathy , central serous chorioretinopathy , retinal vein occlusion , sickle cell retinopathy ) Uncontrolled hypertension ( ≥ 160 systolic ≥95 diastolic ) Glaucoma Dilated pupil diameter le 6 millimeter Subjects history hypersensitivity reaction study drug agent use component study assessment Use topical ocular medication ( artificial tear product ) Anticipated extra intraocular intervention study period High myopia ( refractive error spherical equivalent ≥ 6 diopter ) Optic neuropathy Neurological condition impair vision ( e.g . Parkinson 's disease , multiple sclerosis , Alzheimer 's disease ) Liver disease ( e.g . cirrhosis , hepatitis ) History small bowel surgery Current past use 30 day chloroquine , hydroxychloroquine , chlorpromazine , thioridazine , quinine sulfate , clofazimine , cisplatin , carmustine ( BCNU ) , deferoxamine , amiodorone , isoretinoin , gold Contact lens wearer ( prepared discontinue lens use ) Ophthalmic surgery kind within 3 month prior screen visit Participation interventional clinical study require IRB approval within 3 month prior screen visit study Currently treat cancer disease likely adversely affect participation 2 year study Known AIDS/HIV Current use hydralazine Any finding deem unacceptable Principal Investigator Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AMD</keyword>
	<keyword>Dry AMD</keyword>
	<keyword>Non-Exudative AMD</keyword>
	<keyword>MC-1101</keyword>
</DOC>